Table 2 Descriptive statistics on potentially hazardous prescribing indicators, over 2010–2011 to 2021–2022
Number of consultations at risk for potentially hazardous prescribing (N = 7,623,305 consultation events) | NP Exposed to potentially hazardous prescribing, Permanent GP Numerator (% of denominator) | DP At risk of potentially hazardous prescribing, Permanent GP Denominator | NL Exposed to potentially hazardous prescribing, Locum GP Numerator (% of denominator) | DL At risk of potentially hazardous prescribing, Locum GP Denominator |
|---|---|---|---|---|
Potential harm: GI bleed | ||||
 Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient aged ≥ 65 years (Indicator A) (N = 454,929) | 237,867 (56.5%) | 420,760 | 19,926 (58.3%) | 34,169 |
 Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient with a history of peptic ulceration (Indicator B) (N = 2907) | 1376 (52.6%) | 2617 | 171 (59%) | 290 |
 Prescription of an antiplatelet drug without co-prescription of an ulcer-healing drug, to a patient with a history of peptic ulceration (Indicator C) (N = 3537) | 765 (23.1%) | 3309 | 57 (27.4%) | 228 |
 Prescription of warfarin or DOAC in combination with an oral NSAID (Indicator D) (N = 222,986) | 4567 (2.2%) | 207,655 | 308 (2%) | 15,331 |
 Prescription of warfarin or DOAC and an antiplatelet drug in combination without co-prescription of an ulcer-healing drug (Indicator E) (N = 35,421) | 15,856 (47.7%) | 33,260 | 976 (45.2%) | 2161 |
 Prescription of aspirin in combination with another antiplatelet drug (without co-prescription of an ulcer-healing drug) (Indicator F) (N = 265,499) | 124,950 (50.2%) | 249,148 | 8328 (51%) | 16,351 |
Potential harm: exacerbation of asthma | ||||
 Prescription of a non-selective beta-blocker to a patient with asthma (Indicator G) (N = 163,368) | 11,183 (7.4%) | 150,611 | 1165 (9.1%) | 12,757 |
 Prescription of a long-acting beta-2 agonist inhaler (excluding combination products with inhaled corticosteroid) to a patient with asthma who is not also prescribed an inhaled corticosteroid (Indicator H) (N = 5,917,201) | 50,239 (0.09%) | 5,407,846 | 3293 (0.06%) | 509,355 |
Potential harm: Heart failure | ||||
 Prescription of an oral NSAID to a patient with heart failure (Indicator I) (N = 551,110) | 2610 (0.05%) | 551,110 | 195 (0.003%) | 551,110 |
Potential harm: Stroke | ||||
 Prescription of antipsychotics for > 6 weeks in a patient aged ≥ 65 years with dementia but not psychosis (Indicator J) (N = 6347) | 5601 (93.8%) | 5972 | 335 (89.3%) | 375 |